Adrian B. Tigu

Louis Pasteur Street 4-6
Cluj-napoca, CJ 400349, Romania

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Therapy-Induced Cellular Senescence in Non-Hodgkin Lymphomas, with Emphasis on Aggressive B-Cell Subtypes: Molecular Mechanisms and Emerging Drug Targets.

Therapy-Induced Cellular Senescence in Non-Hodgkin Lymphomas, with Emphasis on Aggressive B-Cell Subtypes: Molecular Mechanisms and Emerging Drug Targets.

Journal: Current cancer drug targets

Published: February 01, 2026

Integrating venetoclax-based targeted and/or immune therapies for chronic lymphocytic leukemia.

Integrating venetoclax-based targeted and/or immune therapies for chronic lymphocytic leukemia.

Journal: Critical reviews in oncology/hematology

Published: December 14, 2025

The crosstalk between epigenetics and metabolism in the malignant cell.

The crosstalk between epigenetics and metabolism in the malignant cell.

Journal: Discover oncology

Published: December 10, 2025

MicroRNAs as Diagnostic and Prognostic Biomarkers in Melanoma and Non-Melanoma Skin Cancers: An Updated Review.

MicroRNAs as Diagnostic and Prognostic Biomarkers in Melanoma and Non-Melanoma Skin Cancers: An Updated Review.

Journal: Diagnostics (Basel, Switzerland)

Published: November 22, 2025

Targeting inflammation and oxidative stress in experimental colitis through IL-6 siRNA and ascorbic acid co-loaded trimethyl chitosan nanoparticles.

Targeting inflammation and oxidative stress in experimental colitis through IL-6 siRNA and ascorbic acid co-loaded trimethyl chitosan nanoparticles.

Journal: International journal of pharmaceutics

Published: October 06, 2025

Proteolysis targeting chimeric-based technology in myeloma and lymphoma.

Proteolysis targeting chimeric-based technology in myeloma and lymphoma.

Journal: Molecular cancer therapeutics

Published: September 22, 2025

Proteolysis Targeting Chimeric-Based Technology in Myeloma and Lymphoma.

Proteolysis Targeting Chimeric-Based Technology in Myeloma and Lymphoma.

Journal: Molecular cancer therapeutics

Published: September 22, 2025

In-depth analysis for TKI-driven real-world management of 201 CML patients using TFR.

In-depth analysis for TKI-driven real-world management of 201 CML patients using TFR.

Journal: Frontiers in pharmacology

Published: July 25, 2025

Adoptive cellular therapies in non-Hodgkin lymphomas.

Adoptive cellular therapies in non-Hodgkin lymphomas.

Journal: Best practice & research. Clinical haematology

Published: May 13, 2025

Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma.

Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma.

Journal: Biomarker research

Published: May 02, 2025

Adoptive cellular therapies in multiple myeloma.

Adoptive cellular therapies in multiple myeloma.

Journal: Best practice & research. Clinical haematology

Published: April 23, 2025

Epigenetic Therapies in Melanoma-Targeting DNA Methylation and Histone Modification.

Epigenetic Therapies in Melanoma-Targeting DNA Methylation and Histone Modification.

Journal: Biomedicines

Published: April 01, 2025

Showing 1-12 of 58

Last Updated: 09/26/2026